Musings from The Power List: John Maher
By John Maher
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
False
Advertisement
Latest
Development & Clinical
Regulation & Standards
Business & Trends
Technology & Manufacturing
Sponsored
From Training Burden to Training Value
August 14, 2026
Why effective study training depends on relevance, timing, and oversight.
0 min read
Why Cell Therapy Needs a Digital Backbone
August 13, 2026
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
8 min read
Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?
August 12, 2026
NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients
11 min read
Musings from The Power List: Ann Cleves
By Ann Cleeves
August 11, 2026
Ann Cleves on why the future of small-molecule drug discovery lies beyond the rule of five
3 min read
This Week’s CGT News: In Vivo CAR T Draws Major Investment
August 10, 2026
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
3 min read
Building Commercial Readiness in Advanced Therapies
August 10, 2026
Why early process development, analytical planning, and tech transfer can shape the future of cell and gene therapy manufacturing
5 min read
Musings from The Power List: Ali Pashazadeh
By Ali Pashazadeh
August 7, 2026
Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier
7 min read
Moving Glycosylation Control Upstream
August 6, 2026
Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.
7 min read
What Did ASCO 2026 Reveal About the Future of Oncology?
By James Strachan
August 6, 2026
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
8 min read
